The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Population Pharmacokinetic Modeling of Palbociclib in Pediatric Patients with Recurrent or Refractory Tumors
Hadigol M, Nanavati C, Lee K, Hoffman J, Wang D
Presentation
RANDOMIZED PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA
Laetsch TW, Kutluk MT, Rastogi S, Kang HJ, Morgenstern D, Juszczak-Kosela KA, Muscal JA, Zhang Z, Holynskyj A, Aslan N, Weigel BJ, Janeway KA, Hawkins DS, Collier AB III
Poster
Evaluation of Palbociclib and Combinatorial Chemotherapy Pharmacokinetics in Pediatric Patients with Recurrent or Refractory Solid Tumors
Nanavati C, Winton J, Juszczak-Kosela KA, Laetsch TW, Weigel BJ, Fox E, Watt T, Macy ME, Lee K, Hoffman J